CHARLES RIVER LABORATORIES (CRL) Stock Price & Overview

NYSE:CRL • US1598641074

Current stock price

165.89 USD
+6.7 (+4.21%)
At close:
165.89 USD
0 (0%)
After Hours:

The current stock price of CRL is 165.89 USD. Today CRL is up by 4.21%. In the past month the price decreased by -1%. In the past year, price increased by 6.65%.

CRL Key Statistics

52-Week Range91.8609 - 228.88
Current CRL stock price positioned within its 52-week range.
1-Month Range149.635 - 182.65
Current CRL stock price positioned within its 1-month range.
Market Cap
8.167B
P/E
16.14
Fwd P/E
14.88
EPS (TTM)
10.28
Dividend Yield
N/A

CRL Stock Performance

Today
+4.21%
1 Week
+5.59%
1 Month
-1.00%
3 Months
-18.55%
Longer-term
6 Months +11.67%
1 Year +6.65%
2 Years -38.77%
3 Years -17.80%
5 Years -42.76%
10 Years +118.45%

CRL Stock Chart

CHARLES RIVER LABORATORIES / CRL Daily stock chart

CRL Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CRL. When comparing the yearly performance of all stocks, CRL is a bad performer in the overall market: 72.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CRL Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CRL. Both the profitability and the financial health of CRL get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRL Earnings

On February 18, 2026 CRL reported an EPS of 2.39 and a revenue of 994.23M. The company beat EPS expectations (0.98% surprise) and missed revenue expectations (-0.27% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 18, 2026
PeriodQ4 / 2025
EPS Reported$2.39
Revenue Reported994.227M
EPS Surprise 0.98%
Revenue Surprise -0.27%

CRL Forecast & Estimates

23 analysts have analysed CRL and the average price target is 206.28 USD. This implies a price increase of 24.34% is expected in the next year compared to the current price of 165.89.

For the next year, analysts expect an EPS growth of 8.47% and a revenue growth 0.2% for CRL


Analysts
Analysts78.26
Price Target206.28 (24.35%)
EPS Next Y8.47%
Revenue Next Year0.2%

CRL Groups

Sector & Classification

CRL Financial Highlights

Over the last trailing twelve months CRL reported a non-GAAP Earnings per Share(EPS) of 10.28. The EPS decreased by -0.39% compared to the year before.


Income Statements
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Industry RankSector Rank
PM (TTM) N/A
ROA -2.02%
ROE -4.56%
Debt/Equity 0.68
Chartmill High Growth Momentum
EPS Q2Q%-10.15%
Sales Q2Q%-0.83%
EPS 1Y (TTM)-0.39%
Revenue 1Y (TTM)-0.85%

CRL Ownership

Ownership
Inst Owners110.03%
Shares49.23M
Float48.67M
Ins Owners0.94%
Short Float %7.3%
Short Ratio3.54

About CRL

Company Profile

CRL logo image Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Company Info

IPO: 2000-06-23

CHARLES RIVER LABORATORIES

251 Ballardvale St

Wilmington MASSACHUSETTS 01887 US

CEO: James C. Foster

Employees: 18300

CRL Company Website

CRL Investor Relations

Phone: 17812226000

CHARLES RIVER LABORATORIES / CRL FAQ

What does CRL do?

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.


What is the stock price of CHARLES RIVER LABORATORIES today?

The current stock price of CRL is 165.89 USD. The price increased by 4.21% in the last trading session.


Does CHARLES RIVER LABORATORIES pay dividends?

CRL does not pay a dividend.


What is the ChartMill technical and fundamental rating of CRL stock?

CRL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Which stock exchange lists CRL stock?

CRL stock is listed on the New York Stock Exchange exchange.


What is the GICS sector and industry of CRL stock?

CHARLES RIVER LABORATORIES (CRL) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Can you provide the short interest for CRL stock?

The outstanding short interest for CHARLES RIVER LABORATORIES (CRL) is 7.3% of its float.